{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T15:04:25Z","timestamp":1776179065694,"version":"3.50.1"},"reference-count":28,"publisher":"Consortium of Multiple Sclerosis Centers","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:p>Background: Physicians must weigh the benefits against the risk of progressive multifocal leukoencephalopathy (PML) in patients treated with natalizumab, especially beyond 2 years. However, disability progression associated with switching therapies versus continuing natalizumab therapy after 2 years has not been fully evaluated.<\/jats:p>\n               <jats:p>Methods: In this retrospective analysis using the NARCOMS Registry, disability progression (Patient-Determined Disease Steps [PDDS] scale) and physical health-related quality of life (HRQOL) worsening (12-item Short Form Health Status Survey Physical Component Score [SF-12 PCS]) were compared between participants switching to fingolimod (n = 50) or interferon beta (IFN\u03b2)\/glatiramer acetate (GA) (n = 71) therapy and those continuing natalizumab (n = 406) after 2 years or more of treatment (median follow-up: natalizumab, 4 years; fingolimod, 4.5 years; IFN\u03b2\/GA, 5 years).<\/jats:p>\n               <jats:p>Results: Participants continuing to take natalizumab had less disability progression (mean PDDS change: natalizumab, 0.3; fingolimod, 0.6; IFN\u03b2\/GA, 0.7; P = .0036), were less likely to report disability progression (proportion with PDDS increase: natalizumab, 31%; fingolimod, 46%; IFN\u03b2\/GA, 42%; P = .0296), and had less worsening in physical HRQOL (mean SF-12 PCS change: natalizumab, \u22121.4; fingolimod, \u22122.8; IFN\u03b2\/GA, \u22124.6; P = .0476) than those switching treatment.<\/jats:p>\n               <jats:p>Conclusions: Although all medication groups exhibited some level of worsening, switching from natalizumab treatment after 2 years was associated with increased disability progression and worsening physical HRQOL. The risk of disability progression from disease activity and the risk of PML should be considered when making natalizumab treatment decisions.<\/jats:p>","DOI":"10.7224\/1537-2073.2014-113","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T11:32:16Z","timestamp":1455622336000},"page":"230-238","source":"Crossref","is-referenced-by-count":4,"title":["Disability Progression After Switching from Natalizumab to Fingolimod or Interferon Beta\/Glatiramer Acetate Therapies"],"prefix":"10.7224","volume":"18","author":[{"given":"Stacey S.","family":"Cofield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Fox","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuula","family":"Tyry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amber R.","family":"Salter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"Campagnolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4242","reference":[{"key":"2020060301091819600_i1537-2073-18-5-230-b1","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"2020060301091819600_i1537-2073-18-5-230-b2","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"O'Connor","year":"2014","journal-title":"Neurology"},{"key":"2020060301091819600_i1537-2073-18-5-230-b3","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020060301091819600_i1537-2073-18-5-230-b4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/WNF.0b013e31824644e6","article-title":"Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort","volume":"35","author":"Kallweit","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"2020060301091819600_i1537-2073-18-5-230-b5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1352458514536085","article-title":"Age-dependent effects on the treatment response of natalizumab in MS patients","volume":"21","author":"Matell","year":"2015","journal-title":"Mult Scler"},{"key":"2020060301091819600_i1537-2073-18-5-230-b6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"2020060301091819600_i1537-2073-18-5-230-b7","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"2020060301091819600_i1537-2073-18-5-230-b8","article-title":"Biogen Idec Inc medical information website"},{"key":"2020060301091819600_i1537-2073-18-5-230-b9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1474-4422(11)70149-1","article-title":"Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring","volume":"10","author":"Kappos","year":"2011","journal-title":"Lancet Neurol"},{"key":"2020060301091819600_i1537-2073-18-5-230-b10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1212\/WNL.45.2.251","article-title":"Disease steps in multiple sclerosis: a simple approach to evaluate disease progression","volume":"45","author":"Hohol","year":"1995","journal-title":"Neurology"},{"key":"2020060301091819600_i1537-2073-18-5-230-b11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","article-title":"A 12-item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity","volume":"34","author":"Ware","year":"1996","journal-title":"Med Care"},{"key":"2020060301091819600_i1537-2073-18-5-230-b12","article-title":"NARCOMS Registry website"},{"key":"2020060301091819600_i1537-2073-18-5-230-b13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/135245859900500508","article-title":"Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression","volume":"5","author":"Hohol","year":"1999","journal-title":"Mult Scler"},{"key":"2020060301091819600_i1537-2073-18-5-230-b14","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1177\/1352458507078388","article-title":"Validity of performance scales for disability assessment in multiple sclerosis","volume":"13","author":"Marrie","year":"2007","journal-title":"Mult Scler"},{"key":"2020060301091819600_i1537-2073-18-5-230-b15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2377-13-37","article-title":"Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis","volume":"13","author":"Learmonth","year":"2013","journal-title":"BMC Neurol"},{"key":"2020060301091819600_i1537-2073-18-5-230-b16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/01312067-200902020-00006","article-title":"Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey","volume":"2","author":"Kamat","year":"2009","journal-title":"The Patient"},{"key":"2020060301091819600_i1537-2073-18-5-230-b17","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/ana.21163","article-title":"Health-related quality of life in multiple sclerosis: effects of natalizumab","volume":"62","author":"Rudick","year":"2007","journal-title":"Ann Neurol"},{"key":"2020060301091819600_i1537-2073-18-5-230-b18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7224\/1537-2073.2012-034","article-title":"Treatment discontinuation and disease progression with injectable disease-modifying therapies","volume":"15","author":"Fox","year":"2013","journal-title":"Int J MS Care"},{"key":"2020060301091819600_i1537-2073-18-5-230-b19","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O'Connor","year":"2011","journal-title":"Neurology"},{"key":"2020060301091819600_i1537-2073-18-5-230-b20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1212\/01.wnl.0000327341.89587.76","article-title":"Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy","volume":"72","author":"Stuve","year":"2009","journal-title":"Neurology"},{"key":"2020060301091819600_i1537-2073-18-5-230-b21","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","article-title":"MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study","volume":"82","author":"Fox","year":"2014","journal-title":"Neurology"},{"key":"2020060301091819600_i1537-2073-18-5-230-b22","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jamaneurol.2014.1200","article-title":"Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP study)","volume":"71","author":"Clerico","year":"2014","journal-title":"JAMA Neurol"},{"key":"2020060301091819600_i1537-2073-18-5-230-b23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1352458510389103","article-title":"Course of relapsing-remitting multiple sclerosis before, during and after natalizumab","volume":"17","author":"Kaufman","year":"2011","journal-title":"Mult Scler"},{"key":"2020060301091819600_i1537-2073-18-5-230-b24","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00415-011-5996-y","article-title":"De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate","volume":"258","author":"Havla","year":"2011","journal-title":"J Neurol"},{"key":"2020060301091819600_i1537-2073-18-5-230-b25","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1352458512464282","article-title":"Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings","volume":"18","author":"Rinaldi","year":"2012","journal-title":"Mult Scler"},{"key":"2020060301091819600_i1537-2073-18-5-230-b26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10072-013-1527-1","article-title":"Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up","volume":"35","author":"Melis","year":"2014","journal-title":"Neurol Sci"},{"key":"2020060301091819600_i1537-2073-18-5-230-b27","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1212\/WNL.0000000000000283","article-title":"Fingolimod after natalizumab and the risk of short-term relapse","volume":"82","author":"Jokubaitis","year":"2014","journal-title":"Neurology"},{"key":"2020060301091819600_i1537-2073-18-5-230-b28","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/aje\/kwj047","article-title":"Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect","volume":"163","author":"Kurth","year":"2006","journal-title":"Am J Epidemiol"}],"container-title":["International Journal of MS Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/18\/5\/230\/2089470\/1537-2073_2014-113.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/ijmsc\/article-pdf\/18\/5\/230\/2089470\/1537-2073_2014-113.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T21:11:50Z","timestamp":1752786710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijmsc.org\/view\/disability-progression-after-switching-from-natalizumab-to-fingolimod-or-interferon-beta-glatiramer-acetate-therapies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,1]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.7224\/1537-2073.2014-113","relation":{},"ISSN":["1537-2073"],"issn-type":[{"value":"1537-2073","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9,1]]}}}